

Editorial

Inaugural editorial: A new journey into
neurology and neuroscienceYun Xu^{1†*} and Anthony Rudd^{2†*}¹Department of Neurology, Drum Tower Hospital, Nanjing University Medical School, Nanjing, China²King's College London, United Kingdom

We are proud to introduce you to the inaugural issue of *Advanced Neurology*, a new journal published by AccScience Publishing (Singapore) Pte. Ltd. *Advanced Neurology* is a peer-reviewed and open-access journal that aims to publish and disseminate novel research on basic, clinical, and translational medicine related to neurological diseases. The journal's mission is to advance our understanding of the diseases related to the nervous system and to provide a platform to showcase the latest findings in fundamental research and clinical research as well as present new ideas that might contribute to the improvement of neurological clinical practice. The target audience of *Advanced Neurology* includes physicians, epidemiologists and neuroscientists working in the disciplines of neurology, neurosurgery, neuroimaging, neurointervention, neuropsychology, and so on.

The main focus of *Advanced Neurology* is to tackle the problems and unravel the questions in neurological disorders, such as neurodegenerative disease, cerebrovascular disease, epilepsy and movement disorder, neuroimmune disease, neurological infection, and muscle disease. Pursuant to the journal's focus, we are particularly interested in papers related to the study of pathological mechanisms, development of new medicines, clinical research, translational research, and big data analysis. The journal's planned publication frequency is four issues per year, and a double-blind peer review process will be applied to all relevant submissions. *Advanced Neurology* will publish original research articles, review articles, case reports, meta-analyses, and perspective articles.

In addition, it is a great honor to lead and work with an editorial board that is not only international but also inherently multi-disciplinary in its academic directions. The current board members come from the United States, the United Kingdom, Canada, Germany, China, Singapore, Brazil, and Pakistan. I am sure the board will grow more diverse in terms of members' region of origin and expertise. *Advanced Neurology* also aspires to demonstrate quality, integrity, and innovation. We strive to ensure that the quality and standards of *Advanced Neurology* stand out among other open-access journals in the same categories. We also aim to be indexed by PubMed and Science Citation Index Expanded as soon as possible. Once this is granted the indexing is retrospective, so all articles published from the start of the journal will be listed.

Despite the existence of numerous journals published in the field of neurology, we consider that the need to deliver quick solutions and insights into neurological disorders is currently unmet. In addition, a common platform where physicians and neuroscientists publish research on peripheral topics and research with negative results is lacking. Thus, these factors drive us to launch a new journal to address the inadequacies in the current publishing landscape. Our primary goal is to publish basic research, clinical research, and translational research that focus on the prevention of neurological diseases, clinical diagnosis and treatment, and address urgent clinical conundrums from different

[†]Professor Yun Xu is the Editor-in-Chief of *Advanced Neurology*, and Professor Anthony Rudd is the Co-Editor-in-Chief of *Advanced Neurology*.

***Corresponding authors:**
Yun Xu (xuyun20042001@aliyun.com)
Anthony Rudd (anthony.rudd@kcl.ac.uk)

Citation: Xu Y, Rudd A, 2022, Inaugural editorial: A new journey into neurology and neuroscience. *Adv Neuro*, 1(1): 53.
<https://doi.org/10.36922/an.v1i1.53>

Received: March 17, 2022

Published Online: April 8, 2022

Copyright: © 2022 Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution License, permitting distribution, and reproduction in any medium, provided the original work is properly cited.

Publisher's Note: AccScience Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

aspects and levels. Thus, as long as the research is original, innovative, and significant for clinical work, we will consider them valuable and significant to the literature of the neurology and neuroscience research. We summarize the strong points of *Advanced Neurology* in the following:

1. The journal encompasses a wide range of research topics and integrates multiple disciplines surrounding neurological diseases, to push forward the development of neurology and neuroscience and provide guidance to clinical work.
2. The journal welcomes various types of articles, including original research, review articles, letters, case reports, opinion pieces and so on.
3. The journal adopts an efficient workflow to process all submissions. The editors will make a preliminary decision within 7 days, and the first editorial decision within 30 days. Constructive comments will be contributed by peer reviewers and editors to guide authors in revising the papers that are considered for publication.

The first issue of *Advanced Neurology* contains articles about stroke, cerebral small vessel disease (CSVD), Alzheimer's disease (AD), and Parkinson's disease (PD) in the form of original article, review, case report, meta-analysis, and basic research.

At present, one of the biggest predicaments for clinical practice is a lack of effective medicine for the treatment of AD. The first original research article we have published shows that the intracellular cAMP receptor EPAC2 caused the abnormal hyperphosphorylation at multiple AD-associated epitopes by activating CDK5 in a classical AD model of Tg2576 mice. This article sheds light on an important mechanism and suggests a new therapeutic target for AD. Aducanumab is so far the only anti-A β drug approved by the US Food and Drug Administration for AD, which can significantly reduce brain A β deposition (a hallmark of AD). To avoid side effects of aducanumab, the experts of "Pre-AD Alliance of China" discussed and reached a consensus on the most common and

important adverse reaction, that is, amyloid-related imaging abnormalities (ARIA), in which the mechanisms, risk factors, identification methods, and administration processes of ARIA are discussed.

The second original research article is about CSVD. In this article, the authors suggest that decreased cortical thickness, but normal ReHo in right anterior cingulate gyrus, right cuneus, bilateral insula, and right middle temporal gyrus could predict cognitive impairment in CSVD patients. Therefore, this provides valuable guidance for the early intervention of CSVD. The next article presents the meta-analysis of the manifestations and outcomes of COVID-19-associated acute ischemic stroke using data from PubMed, Embase, and Web of Science up to November 29, 2021. Another systematic review published in this inaugural issue is about gastrointestinal symptoms and the possible mechanisms in the early stages of PD, which is of great significance not only for clinical diagnosis and treatment but also for basic research.

The third review article summarizes the function and mechanism of reactive oxygen species (ROS) mediated by TRPM2 in neurological disorders, including PD, AD, stroke, traumatic brain injury, and depressive disorders. It also provides strategies to inhibit ROS, common pathologic reactions of above-mentioned diseases by controlling TRPM2. Finally, a case report indicates that large artery atherosclerosis could be the etiology of stroke in patient with multiple infarcts, which was confirmed by territorial arterial spin labeling perfusion magnetic resonance imaging.

We hope that our readers find the articles in the inaugural issue of *Advanced Neurology* inspiring to their clinical and research work. Furthermore, we sincerely welcome submissions from you, to publish new research, insights, and results in the upcoming issues of *Advanced Neurology*. Your trust is of great importance to keeping the journal dynamic and bringing value to physicians and researchers in this field.